<code id='A2A520F184'></code><style id='A2A520F184'></style>
    • <acronym id='A2A520F184'></acronym>
      <center id='A2A520F184'><center id='A2A520F184'><tfoot id='A2A520F184'></tfoot></center><abbr id='A2A520F184'><dir id='A2A520F184'><tfoot id='A2A520F184'></tfoot><noframes id='A2A520F184'>

    • <optgroup id='A2A520F184'><strike id='A2A520F184'><sup id='A2A520F184'></sup></strike><code id='A2A520F184'></code></optgroup>
        1. <b id='A2A520F184'><label id='A2A520F184'><select id='A2A520F184'><dt id='A2A520F184'><span id='A2A520F184'></span></dt></select></label></b><u id='A2A520F184'></u>
          <i id='A2A520F184'><strike id='A2A520F184'><tt id='A2A520F184'><pre id='A2A520F184'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:34387
          glum Benjamin — health insurance coverage from STAT
          Adobe

          Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

          Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.

          advertisement

          They’re planning on taking a different tack with biotech venture capital. For starters, Scion plans to work on a significantly longer timeframe. Most firms in existence today write checks, help investments grow, and find a way to recoup their money in a 10-year timeframe. Scion is doubling that, setting a 20-year plan for its first fund.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          Let's speed up science by embracing open access publishing
          Let's speed up science by embracing open access publishing

          APStockSixyearsago,HarvardscientistJayBradnerdiscoveredsomethingunusual.Hislaboratoryhadisolatedamol

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Europe sees delivery challenges ahead on Alzheimer's therapies

          VialsandpackagingforLeqembi,anewAlzheimer'smedicationapprovedintheU.S.,butnotyetinEurope.Illustratio